MedTrace Logo

Modulation of Gut Microbiota in End-stage Renal Disease

NCT02568891 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-12-13

No results posted yet for this study

Summary

In end-stage renal disease (ESRD) cardiovascular and infectious complications are common. The gut microbiome might play an important pathophysiological role. ESRD is hypothesized to be associated with profound alterations of gut microbiome and gut permeability. The investigators aim to test whether a multispecies probiotic mixture is able to revert the microbiome changes and decrease gut permeability. Furthermore the investigators aim to test whether this improvement in microbiome composition and gut permeability is also associated with improvements in endotoxemia, uremia and cardiovascular risk factors.

Conditions

  • End-stage Renal Disease

Interventions

DIETARY_SUPPLEMENT

Probiotic

multispecies probiotic

DIETARY_SUPPLEMENT

Placebo

matrix

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Vanessa Stadlbauer, MD · Medical University of Graz

  • Harald Sourij, MD · Medical University of Graz

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2020-01-31
Completion
2021-01-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02568891 on ClinicalTrials.gov